Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review

Márcio G. Kiuchi; Murray D. Esler; Gregory D. Fink; John W. Osborn; Christopher T. Banek; Michael Böhm; Kate M. Denton; Gerald F. DiBona; Thomas H. Everett; Guido Grassi; Richard E. Katholi; Mark M. Knuepfer; Ulla C. Kopp; David J. Lefer; Thomas E. Lohmeier; Clive N. May; Felix Mahfoud; Julian F.R. Paton; Roland E. Schmieder; Peter R. Pellegrino; Yehonatan Sharabi; Markus P. Schlaich

doi:10.1016/j.jacc.2019.04.015

Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review

Márcio G. Kiuchi, Murray D. Esler, Gregory D. Fink, John W. Osborn, Christopher T. Banek, Michael Böhm, Kate M. Denton, Gerald F. DiBona, Thomas H. Everett, Guido Grassi, Richard E. Katholi, Mark M. Knuepfer, Ulla C. Kopp, David J. Lefer, Thomas E. Lohmeier, Clive N. May, Felix Mahfoud, Julian F.R. Paton, Roland E. Schmieder, Peter R. PellegrinoYehonatan Sharabi, Markus P. Schlaich

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

Original language	English (US)
Pages (from-to)	3006-3017
Number of pages	12
Journal	Journal of the American College of Cardiology
Volume	73
Issue number	23
DOIs	https://doi.org/10.1016/j.jacc.2019.04.015
State	Published - Jun 18 2019

Bibliographical note

Funding Information:
All authors received honoraria and travel support from Medtronic to present at “The SNS Summit” held in Barcelona in June 2018. Dr. Esler has been supported in part by the Victorian Government's Operational Infrastructure Support Program; has received salary support from an Australian Government NHMRC Senior Principal Research Fellowship; and has been a member of the Advisory Boards of SyMap and Medtronic. Dr. Banek is supported by National Institutes of Health grant K99 HL141650. Drs. Böhm and Mahfoud are supported by Deutsche Gesellschaft für Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft (SFB TRR 219); and have received grant support and personal fees from Medtronic and Recor Medical. Dr. Böhm has received research support and speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, and Novartis. Dr. Denton is supported by an NHMRC research fellowship; and has received travel support from Medtronic. Dr. Everett is supported in part by National Institutes of Health grant R42DA043391 and a Charles Fisch Cardiovascular Research Award endowed by Dr. Suzanne B. Knoebel of the Krannert Institute of Cardiology. Dr. Mahfoud has received research grants from and served on the Speakers Bureau of Medtronic and Recor. Dr. Paton was supported by the British Heart Foundation and the Health Research Council of New Zealand. Dr. Schmieder has received speaker fees, consultancy, and advisory board fees from Ablative Solutions, Medtronic, Recor, and ROX Medical. Dr. Pellegrino has received honoraria and travel support from Medtronic. Dr. Schlaich is supported by an NHMRC Research Fellowship; and has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Keywords

blood pressure
cardiovascular disease
hypertension
renal denervation
sympathetic nervous system

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Review

Access

10.1016/j.jacc.2019.04.015

Fingerprint Dive into the research topics of 'Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review'. Together they form a unique fingerprint.

Cite this

Kiuchi, M. G., Esler, M. D., Fink, G. D., Osborn, J. W., Banek, C. T., Böhm, M., Denton, K. M., DiBona, G. F., Everett, T. H., Grassi, G., Katholi, R. E., Knuepfer, M. M., Kopp, U. C., Lefer, D. J., Lohmeier, T. E., May, C. N., Mahfoud, F., Paton, J. F. R., Schmieder, R. E., ... Schlaich, M. P. (2019). Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73(23), 3006-3017. https://doi.org/10.1016/j.jacc.2019.04.015

Renal Denervation Update From the International Sympathetic Nervous System Summit : JACC State-of-the-Art Review. / Kiuchi, Márcio G.; Esler, Murray D.; Fink, Gregory D.; Osborn, John W.; Banek, Christopher T.; Böhm, Michael; Denton, Kate M.; DiBona, Gerald F.; Everett, Thomas H.; Grassi, Guido; Katholi, Richard E.; Knuepfer, Mark M.; Kopp, Ulla C.; Lefer, David J.; Lohmeier, Thomas E.; May, Clive N.; Mahfoud, Felix; Paton, Julian F.R.; Schmieder, Roland E.; Pellegrino, Peter R.; Sharabi, Yehonatan; Schlaich, Markus P.

In: Journal of the American College of Cardiology, Vol. 73, No. 23, 18.06.2019, p. 3006-3017.

Research output: Contribution to journal › Review article › peer-review

Kiuchi, MG, Esler, MD, Fink, GD, Osborn, JW, Banek, CT, Böhm, M, Denton, KM, DiBona, GF, Everett, TH, Grassi, G, Katholi, RE, Knuepfer, MM, Kopp, UC, Lefer, DJ, Lohmeier, TE, May, CN, Mahfoud, F, Paton, JFR, Schmieder, RE, Pellegrino, PR, Sharabi, Y & Schlaich, MP 2019, 'Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review', Journal of the American College of Cardiology, vol. 73, no. 23, pp. 3006-3017. https://doi.org/10.1016/j.jacc.2019.04.015

Kiuchi, Márcio G. ; Esler, Murray D. ; Fink, Gregory D. ; Osborn, John W. ; Banek, Christopher T. ; Böhm, Michael ; Denton, Kate M. ; DiBona, Gerald F. ; Everett, Thomas H. ; Grassi, Guido ; Katholi, Richard E. ; Knuepfer, Mark M. ; Kopp, Ulla C. ; Lefer, David J. ; Lohmeier, Thomas E. ; May, Clive N. ; Mahfoud, Felix ; Paton, Julian F.R. ; Schmieder, Roland E. ; Pellegrino, Peter R. ; Sharabi, Yehonatan ; Schlaich, Markus P. / Renal Denervation Update From the International Sympathetic Nervous System Summit : JACC State-of-the-Art Review. In: Journal of the American College of Cardiology. 2019 ; Vol. 73, No. 23. pp. 3006-3017.

@article{a3d236d8edf840f48e5cd57ea4636f20,

title = "Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review",

abstract = "Three recent renal denervation studies in both drug-na{\"i}ve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.",

keywords = "blood pressure, cardiovascular disease, hypertension, renal denervation, sympathetic nervous system",

author = "Kiuchi, {M{\'a}rcio G.} and Esler, {Murray D.} and Fink, {Gregory D.} and Osborn, {John W.} and Banek, {Christopher T.} and Michael B{\"o}hm and Denton, {Kate M.} and DiBona, {Gerald F.} and Everett, {Thomas H.} and Guido Grassi and Katholi, {Richard E.} and Knuepfer, {Mark M.} and Kopp, {Ulla C.} and Lefer, {David J.} and Lohmeier, {Thomas E.} and May, {Clive N.} and Felix Mahfoud and Paton, {Julian F.R.} and Schmieder, {Roland E.} and Pellegrino, {Peter R.} and Yehonatan Sharabi and Schlaich, {Markus P.}",

note = "Funding Information: All authors received honoraria and travel support from Medtronic to present at “The SNS Summit” held in Barcelona in June 2018. Dr. Esler has been supported in part by the Victorian Government's Operational Infrastructure Support Program; has received salary support from an Australian Government NHMRC Senior Principal Research Fellowship; and has been a member of the Advisory Boards of SyMap and Medtronic. Dr. Banek is supported by National Institutes of Health grant K99 HL141650. Drs. B{\"o}hm and Mahfoud are supported by Deutsche Gesellschaft f{\"u}r Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft (SFB TRR 219); and have received grant support and personal fees from Medtronic and Recor Medical. Dr. B{\"o}hm has received research support and speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, and Novartis. Dr. Denton is supported by an NHMRC research fellowship; and has received travel support from Medtronic. Dr. Everett is supported in part by National Institutes of Health grant R42DA043391 and a Charles Fisch Cardiovascular Research Award endowed by Dr. Suzanne B. Knoebel of the Krannert Institute of Cardiology. Dr. Mahfoud has received research grants from and served on the Speakers Bureau of Medtronic and Recor. Dr. Paton was supported by the British Heart Foundation and the Health Research Council of New Zealand. Dr. Schmieder has received speaker fees, consultancy, and advisory board fees from Ablative Solutions, Medtronic, Recor, and ROX Medical. Dr. Pellegrino has received honoraria and travel support from Medtronic. Dr. Schlaich is supported by an NHMRC Research Fellowship; and has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2019",

month = jun,

day = "18",

doi = "10.1016/j.jacc.2019.04.015",

language = "English (US)",

volume = "73",

pages = "3006--3017",

journal = "Journal of the American College of Cardiology.",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "23",

}

TY - JOUR

T1 - Renal Denervation Update From the International Sympathetic Nervous System Summit

T2 - JACC State-of-the-Art Review

AU - Kiuchi, Márcio G.

AU - Esler, Murray D.

AU - Fink, Gregory D.

AU - Osborn, John W.

AU - Banek, Christopher T.

AU - Böhm, Michael

AU - Denton, Kate M.

AU - DiBona, Gerald F.

AU - Everett, Thomas H.

AU - Grassi, Guido

AU - Katholi, Richard E.

AU - Knuepfer, Mark M.

AU - Kopp, Ulla C.

AU - Lefer, David J.

AU - Lohmeier, Thomas E.

AU - May, Clive N.

AU - Mahfoud, Felix

AU - Paton, Julian F.R.

AU - Schmieder, Roland E.

AU - Pellegrino, Peter R.

AU - Sharabi, Yehonatan

AU - Schlaich, Markus P.

N1 - Funding Information: All authors received honoraria and travel support from Medtronic to present at “The SNS Summit” held in Barcelona in June 2018. Dr. Esler has been supported in part by the Victorian Government's Operational Infrastructure Support Program; has received salary support from an Australian Government NHMRC Senior Principal Research Fellowship; and has been a member of the Advisory Boards of SyMap and Medtronic. Dr. Banek is supported by National Institutes of Health grant K99 HL141650. Drs. Böhm and Mahfoud are supported by Deutsche Gesellschaft für Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft (SFB TRR 219); and have received grant support and personal fees from Medtronic and Recor Medical. Dr. Böhm has received research support and speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, and Novartis. Dr. Denton is supported by an NHMRC research fellowship; and has received travel support from Medtronic. Dr. Everett is supported in part by National Institutes of Health grant R42DA043391 and a Charles Fisch Cardiovascular Research Award endowed by Dr. Suzanne B. Knoebel of the Krannert Institute of Cardiology. Dr. Mahfoud has received research grants from and served on the Speakers Bureau of Medtronic and Recor. Dr. Paton was supported by the British Heart Foundation and the Health Research Council of New Zealand. Dr. Schmieder has received speaker fees, consultancy, and advisory board fees from Ablative Solutions, Medtronic, Recor, and ROX Medical. Dr. Pellegrino has received honoraria and travel support from Medtronic. Dr. Schlaich is supported by an NHMRC Research Fellowship; and has received consulting fees and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2019/6/18

Y1 - 2019/6/18

N2 - Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

AB - Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

KW - blood pressure

KW - cardiovascular disease

KW - hypertension

KW - renal denervation

KW - sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=85066481995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066481995&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.04.015

DO - 10.1016/j.jacc.2019.04.015

M3 - Review article

C2 - 31196459

AN - SCOPUS:85066481995

VL - 73

SP - 3006

EP - 3017

JO - Journal of the American College of Cardiology.

JF - Journal of the American College of Cardiology.

SN - 0735-1097

IS - 23

ER -